Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2161 - Hepatic functional imaging and genomics to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study:


11 Sep 2017


Poster display session


Translational Research;  Clinical Research




Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367


M. MICHAEL1, W. Liauw2, S. McLachlan3, E. Link4, A. Matera4, M. Thompson5, M. Jefford1, R.J. Hicks5, C. Cullinane6, I. Campbell6, P.J. Beale7, C.S. Karapetis8, T.J. Price9, M.E. Burge10

Author affiliations

  • 1 Division Of Cancer Medicine, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 2 Medical Onclogy, St Geroges Hospital, Sydney/AU
  • 3 Medcial Oncology, St Vincents Hospital, Melbourne/AU
  • 4 Biostatistics And Clinical Trials Centre, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 5 Dept Cancer Imaging, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 6 Division Of Cancer Researchcine, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 7 Medical Oncology, Royal Prince Alfred Hospital, Sydney/AU
  • 8 Medical Oncology, Flinders Medical Centre and Flinders Centre for Innovation in Cancer, Adelaide/AU
  • 9 Medical Oncology, Queen Elizabeth Hospital, 5011 - Woodville/AU
  • 10 Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane/AU


Abstract 2161


Body surface area-based dosing of Irinotecan (IR), has not accounted for its significant pharmacokinetic (PK) and pharmacodynamic (PD) variability. Given IR’s unique metabolism, hepatic functional nuclear imaging (HNI) with probes for hepatic transporters correlated with its PK. This study further evaluated the utility of HNI combined with extensive excretory/metabolic/PD pharmacogenomics (PG) to predict IR PK and PD in patients (pts) treated with FOLFIRI to enable dose individualization.


Eligible pts had advanced colorectal cancer, suitable for 1st/2nd-line FOLFIRI± Bevacizumab. Pts had blood analyzed by Affymetrix DMET™ Plus Array and additional SNPs were genotyped. For HNI, pts were given IV 250MBq 99mTc-IDA and imaging data analyzed for hepatic extraction/excretion parameters (clearance [CL], 1hour retention [1hRET], deconvulutional CL [DeCL], hepatic extraction fraction [HEF]). Pts treated with chemotherapy, q2-weekly, and restaged after 4 cycles. Blood taken for IR and metabolite (SN38, SN38G) analysis on day 1 cycle 1, PK parameters derived by non-compartmental analysis. Statistical correlations were evaluated between (i) IDA HNI and (2) PGs, with IR PK, toxicity, objective response (ORR) and progression-free survival (PFS).


32 pts analysed, 31 pts completed 4 cycles. (1) PK correlates: (a) HNI CL and 1hRET with SN38 Metabolic CL, (P = 0.04) and (b) HNI DeCL with IR AUC(0-∞) (P = 0.04). (2) Grade 3+ diarrhea (N = 4, 13%) predicted by SN38 AUC(0-∞) andMetabolic CL (P = 0.04), and gene variants for SCL22A2 and -28A3, ABCC2, UGT2B17, CYP2C18 and DPYD (P 


Hepatic functional imaging with extensive pharmacogenomics correlated with Irinotecan PK and PD enabling the future development of nomograms to individualize its dosing.

Clinical trial identification

Australian Clinical Trials Registry: ACTRN12610000898055

Legal entity responsible for the study

Peter MacCallum Cancer Centre


Australian Federal Government: National Health and Medical Research Council Project Grant


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.